Israeli Medical Device Company IceCure Receives China Approval for Cancer Treatment System
Israeli firm IceCure Medical has gained China's National Medical Products Administration approval for its ProSense cryoablation system, expanding cancer.
Breaking newsTPS
Published by IsraelFM
Jerusalem, 14 September, 2026 (TPS-IL) — Israeli medical device company IceCure Medical has received regulatory approval from China’s National Medical Products Administration to market its ProSense cryoablation system and associated cryoprobes in China.
Based in Caesarea, IceCure develops minimally invasive technology that uses liquid nitrogen to destroy tumors by freezing them, offering an alternative to surgical tumor removal. The ProSense system is primarily used in treating breast, kidney, bone and lung tumors and is already marketed in the United States, Europe and parts of Asia.